These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Application of In-Silico Reverse Vaccinology for Designing Multi-Epitope Vaccine Against Coronavirus
preprintsubmitted on 07.06.2020, 16:45 and posted on 09.06.2020, 05:35 by Kumar Sharp, Dr. Shubhangi Dange
In absence of any specific medication or vaccine till now, experimentation has reached new heights. With lockdown imposed in almost every country and huge economic losses the search for a suitable vaccine has still been unsuccessful. In this study we have approached through in-silico method or reverse vaccinology taking advantage of the genome sequence of the novel coronavirus. We created a multi-epitope model vaccine which can elicit both humoral as well as cell-mediated immune response. It is also docked with toll-like receptor 8 TLR-8. The sequence obtained is antigenic, non-allergenic and 86.3% residues are in favourable region of Ramachandran plot. This sequence might have good hope of emerging as the vaccine of the current pandemic if studied more in depth.